Astaxanthin for Eye Fatigue / Digital Eye Strain

Verdict: Promising but weak, industry-funded evidence

A few small, manufacturer-funded trials suggest astaxanthin may modestly ease subjective digital eye strain, but the evidence is too weak and conflicted for any health authority or eye-care body to endorse it.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a B (Preliminary Evidence) rather than a higher grade because the entire evidence base is about five small, short Japanese RCTs (n roughly 40-64, 4-12 weeks). They agree directionally: a 2025 children's trial reported a ~27% improvement in Computer Vision Syndrome Questionnaire scores (PMID 40014233), and the foundational Nagaki 2002 trial reported reduced asthenopia and improved accommodation amplitude. That consistency keeps it above the lowest tiers.

But quality is uniformly low. Every trial was funded by an astaxanthin raw-material or supplement maker (Fuji Chemical/AstaReal, BGG Japan, DHC, FANCL), often with company employees as named authors, creating heavy conflict-of-interest and publication-bias risk. Several positive results came from multi-ingredient formulas combining lutein, anthocyanin, or DHA (PMID 34376917; PMC4997915), so the benefit cannot be attributed to astaxanthin alone, and one healthy-adult trial found benefit only in the over-40 subgroup (PMID 36777084). Objective measures such as visual acuity and accommodation frequently failed to reach significance; mainly subjective questionnaires improved.

No independent authority backs this use. EFSA rejected the astaxanthin visual-acuity health claim for insufficient evidence; the FDA recognizes astaxanthin only as a food and color additive, not for any eye benefit; and NIH ODS, Mayo Clinic, Cleveland Clinic, and Harvard Health do not address it. No ophthalmology or optometry society endorses any supplement for digital eye strain, and no Cochrane-level review exists. For these reasons it is published with a warning.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.57
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
75%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.575
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Astaxanthin (AstaReal) Improved Acute and Chronic Digital Eye Strain in Children: A Randomized Double-Blind Placebo-Controlled Trial
PMID: 40014233 2025 RCT (double-blind) n = 64
Finding: 顯著降低數位眼睛疲勞症狀,蝦紅素組 CVS-Q 改善幅度大於安慰劑組,視覺疲勞分數約改善 27%
🟠 Limited quality Effect size: CVS-Q 改善 4.00±4.05 vs 安慰劑 1.72±3.61(組間差約 20%,p<0.0001)
View on PubMed
Effects of diet containing astaxanthin on visual function in healthy individuals: a randomized, double-blind, placebo-controlled, parallel study
PMID: 36777084 2022 RCT (double-blind) n = 59
Finding: 僅在 40 歲以上族群顯示 VDT 作業後優勢眼矯正視力受到保護的差異;40 歲以下無顯著差異
🟠 Limited quality Effect size: 40 歲以上優勢眼矯正視力(VDT 後 6 週):蝦紅素組 -0.126±0.094 vs 安慰劑 -0.038±0.086(p<0.05)
View on PubMed
Effects of anthocyanin, astaxanthin, and lutein on eye functions: a randomized, double-blind, placebo-controlled study
PMID: 34376917 2021 RCT (double-blind) n = 40
Finding: 複方組瞳孔反應百分比顯著改善,調節相關主觀症狀亦有改善;蝦紅素為複方成分之一,無法單獨歸因
🟠 Limited quality Effect size: 瞳孔反應平均差異約 4.4%(雙眼平均)、6.0%(優勢眼)
View on PubMed
Effect of Multiple Dietary Supplement Containing Lutein, Astaxanthin, Cyanidin-3-Glucoside, and DHA on Accommodative Ability
PMID: 2014 RCT (double-blind) n = 48
— See PubMed for details
View on PubMed
Effect of astaxanthin on accommodation and asthenopia (Nagaki et al., Journal of Traditional Medicines 2002;19(5):170-173)
PMID: 2002 RCT (double-blind)
— See PubMed for details
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
Permanently listed, exempt from certification; Salmonid feed, NTE 80 mg/kg source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Cautious
每日食用限量以蝦紅素計為二毫克。蝦紅素作為原料之食品,應標示「十二歲以下兒童、孕婦、哺乳婦女及服用肝臟或新陳代謝疾病相關藥物者,應避免食用」之警語字樣。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-eye-fatigue-INT-astaxanthin-001 繁體中文版 →